Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
Legend Biotech (NASDAQ: LEGN) has announced plans to establish a new 31,000 square-foot state-of-the-art research and development facility in Philadelphia, Pennsylvania. This expansion aims to enhance Legend's cell therapy portfolio and expand its R&D capabilities as a global cell therapy leader. The facility, located at 2300 Market Street, is expected to be completed in the third quarter of 2025 and will eventually house 55 full-time employees.
This new site adds to Legend's existing global R&D organization, which includes over 350 employees worldwide. The company, with over 1,200 employees in the United States, views this expansion as an opportunity to join Philadelphia's growing biotech community, attract top talent, and strengthen partnerships with local research institutions.
Legend Biotech (NASDAQ: LEGN) ha annunciato piani per stabilire un nuovo stabilimento di ricerca e sviluppo all'avanguardia di 31.000 piedi quadrati a Philadelphia, Pennsylvania. Questa espansione mira a migliorare il portafoglio di terapie cellulari di Legend ed ampliare le sue capacità di R&S come leader globale nella terapia cellulare. La struttura, situata al 2300 Market Street, è prevista per essere completata nel terzo trimestre del 2025 e ospiterà in futuro 55 dipendenti a tempo pieno.
Questo nuovo sito si aggiunge all'organizzazione globale di R&S esistente di Legend, che conta oltre 350 dipendenti in tutto il mondo. L'azienda, con oltre 1.200 dipendenti negli Stati Uniti, considera questa espansione come un'opportunità per unirsi alla crescente comunità biotecnologica di Philadelphia, attrarre talenti di alto livello e rafforzare le partnership con le istituzioni di ricerca locali.
Legend Biotech (NASDAQ: LEGN) ha anunciado planes para establecer una nueva instalación de investigación y desarrollo de 31,000 pies cuadrados de última generación en Filadelfia, Pennsylvania. Esta expansión tiene como objetivo mejorar el portafolio de terapias celulares de Legend y ampliar sus capacidades de I+D como líder global en terapia celular. La instalación, ubicada en 2300 Market Street, se espera que esté terminada en el tercer trimestre de 2025 y acogerá eventualmente a 55 empleados a tiempo completo.
Este nuevo sitio se suma a la organización global de I+D existente de Legend, que incluye a más de 350 empleados en todo el mundo. La compañía, que cuenta con más de 1,200 empleados en los Estados Unidos, ve esta expansión como una oportunidad para unirse a la creciente comunidad biotecnológica de Filadelfia, atraer talento de primer nivel y fortalecer las asociaciones con las instituciones de investigación locales.
레전드 바이오텍 (NASDAQ: LEGN)은 필라델피아, 펜실베니아에 31,000 평방피트 규모의 최신 연구개발 시설을 설립할 계획을 발표했습니다. 이번 확장은 레전드의 세포 치료 포트폴리오를 개선하고 글로벌 세포 치료 리더로서 연구개발 역량을 확장하는 것을 목표로 합니다. 이 시설은 2300 Market Street에 위치하며 2025년 3분기에 완공될 예정이며, 이후 55명의 정규직 직원이 근무하게 될 것입니다.
이 새로운 시설은 전 세계 350명 이상의 직원을 포함한 레전드의 기존 글로벌 연구개발 조직에 추가됩니다. 미국에서 1,200명 이상의 직원을 둔 이 회사는 이번 확장을 필라델피아의 성장하는 바이오텍 커뮤니티에 합류하고, 우수 인재를 유치하며, 지역 연구 기관과의 파트너십을 강화할 기회로 보고 있습니다.
Legend Biotech (NASDAQ: LEGN) a annoncé des projets pour établir une nouvelle installation de recherche et développement de 31 000 pieds carrés à la pointe de la technologie à Philadelphie, Pennsylvanie. Cette expansion vise à améliorer le portefeuille de thérapies cellulaires de Legend et à élargir ses capacités de R&D en tant que leader mondial dans la thérapie cellulaire. L'installation, située au 2300 Market Street, devrait être achevée au troisième trimestre 2025 et accueillera éventuellement 55 employés à temps plein.
Ce nouveau site vient s'ajouter à l'organisation mondiale de R&D existante de Legend, qui comprend plus de 350 employés dans le monde entier. L'entreprise, qui compte plus de 1 200 employés aux États-Unis, considère cette expansion comme une occasion de rejoindre la communauté biotechnologique en pleine croissance de Philadelphie, d'attirer des talents de haut niveau et de renforcer les partenariats avec les institutions de recherche locales.
Legend Biotech (NASDAQ: LEGN) hat Pläne angekündigt, eine neue 31.000 Quadratfuß große Forschungs- und Entwicklungseinrichtung in Philadelphia, Pennsylvania, zu errichten. Diese Erweiterung zielt darauf ab, das Zelltherapie-Portfolio von Legend zu verbessern und die F&E-Kapazitäten als globaler Marktführer im Bereich Zelltherapie auszubauen. Die Einrichtung, die sich auf der 2300 Market Street befindet, soll im dritten Quartal 2025 fertiggestellt werden und wird schließlich 55 Vollzeitmitarbeiter beherbergen.
Dieser neue Standort ergänzt die bestehende globale F&E-Organisation von Legend, die weltweit über 350 Mitarbeiter beschäftigt. Das Unternehmen, das mehr als 1.200 Mitarbeiter in den Vereinigten Staaten hat, sieht diese Expansion als Gelegenheit, sich der wachsenden Biotechnologie-Gemeinschaft von Philadelphia anzuschließen, Top-Talente zu gewinnen und Partnerschaften mit lokalen Forschungseinrichtungen zu stärken.
- Expansion of R&D capabilities with a new 31,000 square-foot facility
- Strengthening position in the growing Philadelphia biotech hub
- Potential for attracting top talent and fostering partnerships with local research institutions
- Addition of 55 full-time employees at the new facility
- None.
Insights
The establishment of a new R&D facility in Philadelphia marks a significant expansion for Legend Biotech, enhancing its capabilities in cell therapy development. The 31,000 square-foot facility, set to be operational by Q3 2025, demonstrates a substantial commitment to innovation and pipeline advancement.
This strategic move positions Legend within a thriving biotech hub, potentially accelerating research through collaborations with local institutions. The addition of 55 full-time employees to the Philadelphia site will bolster the company's R&D workforce, which already includes over 350 employees globally.
The investment in this facility suggests Legend is prioritizing long-term growth and maintaining its competitive edge in the cell therapy space. It's a positive indicator for the company's future research capabilities and could lead to faster development of new therapies, ultimately benefiting both the company and patients.
Legend Biotech's expansion into Philadelphia is a strategic move that could yield significant benefits:
- Enhanced talent acquisition in a competitive biotech market
- Potential for increased collaboration with academic institutions
- Strengthened R&D capabilities, potentially accelerating product development
This investment signals confidence in the company's growth trajectory and commitment to innovation. For investors, it suggests a long-term vision focused on maintaining market leadership in cell therapies. While the immediate financial impact may be , the potential for accelerated pipeline development and increased intellectual property could drive future value creation.
The move aligns with industry trends of biotech companies clustering in innovation hubs to leverage shared resources and talent pools. This could lead to improved operational efficiencies and reduced time-to-market for new therapies, positively impacting Legend's competitive position in the long run.
New 31,000 square-foot facility will enhance Legend’s leading cell therapy portfolio and expand Legend’s R&D capabilities as a global cell therapy leader
SOMERSET, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), announced it is establishing a new, state-of-the-art research and development (R&D) facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies.
“This new facility underscores Legend’s commitment to R&D, as we make key investments that will advance our pipeline and strengthen our leadership position in cell therapy innovation,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “We are excited to join the Philadelphia biotech community, a growing innovation hub and a prime location to attract top talent and strengthen our partnerships with local, leading research institutions. We look forward to bolstering our cell therapy capabilities at this new site.”
The new Philadelphia facility adds to Legend’s existing global R&D organization, which encompasses more than 350 employees across the globe. The 31,000-square-foot facility at 2300 Market Street is expected to be complete in the third quarter of 2025. Legend, which has over 1,200 employees in the United States, anticipates 55 full-time employees will eventually be based in the Philadelphia facility. This expansion builds on Legend’s existing R&D footprint in the U.S., including a facility in Piscataway, New Jersey.
“Legend’s investment in this new site will offer our world-class research team an optimal environment and resources to expand on our cutting-edge innovation,” said Guowei Fang, Ph.D., Chief Scientific Officer and Head of Business Development of Legend Biotech. “We are particularly enthusiastic about the proximity to leading academic institutions in Philadelphia that are at the forefront of medical breakthroughs as we focus on advancing our sustainable pipeline of innovative cell therapies.”
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.
Learn more at www.legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s strategies and objectives, and the potential benefits of Legend Biotech’s product candidates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third-party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 19, 2024. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated, or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
jessie.yeung@legendbiotech.com
PRESS CONTACT:
Mary Ann Ondish
Tel: (914) 552-4625
media@legendbiotech.com
FAQ
When will Legend Biotech's new Philadelphia R&D facility be completed?
How many employees will work at Legend Biotech's (LEGN) new Philadelphia facility?
What is the purpose of Legend Biotech's (LEGN) new Philadelphia facility?
How many employees does Legend Biotech (LEGN) have in the United States?
